These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37536184)

  • 1. Baseline and early changes in the neutrophil-lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy.
    Ouyang H; Xiao B; Huang Y; Wang Z
    Int Immunopharmacol; 2023 Oct; 123():110703. PubMed ID: 37536184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
    Li M; Spakowicz D; Burkart J; Patel S; Husain M; He K; Bertino EM; Shields PG; Carbone DP; Verschraegen CF; Presley CJ; Otterson GA; Kendra K; Owen DH
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2541-2546. PubMed ID: 31367835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
    Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
    Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    He LN; Fu S; Zhang X; Hu Q; Du W; Li H; Chen T; Chen C; Jiang Y; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang L; Hong S
    Lung Cancer; 2021 Aug; 158():1-8. PubMed ID: 34087538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic biomarkers in metastatic colorectal cancer: delta prognostic nutritional index, delta neutrophil to lymphocyte ratio, and delta platelet to lymphocyte ratio.
    Kocak MZ; Coban S; Araz M; Eryilmaz MK; Artac M
    Support Care Cancer; 2023 May; 31(6):357. PubMed ID: 37246994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.
    He W; Yin C; Guo G; Jiang C; Wang F; Qiu H; Chen X; Rong R; Zhang B; Xia L
    Med Oncol; 2013 Mar; 30(1):439. PubMed ID: 23307251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Metastatic Colorectal Cancer.
    Bulut G; Ozdemir ZN
    J Gastrointest Cancer; 2022 Mar; 53(1):1-6. PubMed ID: 33686459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer.
    Matsuda A; Yamada T; Matsumoto S; Sakurazawa N; Kawano Y; Shinozuka E; Sekiguchi K; Suzuki H; Yoshida H
    Anticancer Res; 2019 Aug; 39(8):4343-4350. PubMed ID: 31366528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.
    Chua W; Charles KA; Baracos VE; Clarke SJ
    Br J Cancer; 2011 Apr; 104(8):1288-95. PubMed ID: 21448173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
    Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D
    Ann Oncol; 2018 Apr; 29(4):924-930. PubMed ID: 29324972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.
    Viñal D; Gutierrez-Sainz L; Martinez D; Garcia-Cuesta JA; Pedregosa J; Villamayor J; Ostios L; Sanchez-Cabrero D; Higuera O; Pinto A; Rodriguez-Salas N; Espinosa E; de Castro J; Feliu J
    Clin Transl Oncol; 2021 Jun; 23(6):1185-1192. PubMed ID: 33226553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study.
    Inamoto S; Kawada K; Okamura R; Hida K; Sakai Y
    Int J Colorectal Dis; 2019 Jul; 34(7):1303-1315. PubMed ID: 31177316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
    Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
    Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
    Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
    World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.